James M. Frates, Director at Sage Therapeutics, Inc. (SAGE), bought 1,810 shares at $55.10 ($100K) on 2021-06-16, disclosed to the SEC on 2021-06-17.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| AMLX | SELL | 2026-02-04 | $52K | — | Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |